1 week Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary GoalZacks
SYRS stock plummets as late-stage cancer study of lead candidate fails to achieve its primary endpoint leading to the termination of the study.
XSYRS stock plummets as late-stage cancer study of lead candidate fails to achieve its primary endpoint leading to the termination of the study.
X